Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment. Academic Article uri icon

Overview

abstract

  • Twenty-six patients with advanced prostatic carcinoma refractory to conventional endocrine treatment were treated with a new oral nonsteriodal antiandrogen, flutamide. There were 6 responders and 20 failures. No serious toxicity attributable to flutamide was observed.

publication date

  • August 1, 1975

Research

keywords

  • Anilides
  • Flutamide
  • Prostatic Neoplasms

Identity

Scopus Document Identifier

  • 0016778761

Digital Object Identifier (DOI)

  • 10.1016/0090-4295(75)90704-9

PubMed ID

  • 1145932

Additional Document Info

volume

  • 6

issue

  • 2